Evidence map›Paper›PMID 41617393›Full record

ArticleJournal for immunotherapy of cancer2026

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.

Eileen M O'Reilly, Christopher R Cabanski, Jaclyn P Lyman, Zev A Wainberg, George A Fisher, Robert A Wolff, Andrew H Ko, Mark H O'Hara, Christine N Spencer, Jia Xin Yu and 13 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04787991 (A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04787991 phase1completednot on this map

A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)

TypeinterventionalSponsorCancer Insight, LLCRan2021 to 2025Enrolled45ConditionsMetastatic Pancreatic AdenocarcinomaArmsNivolumab (Cohort A), Ipilimumab (Cohort A, B and C), Hydroxychloroquine (HCQ) (Cohort B), Nab-paclitaxel (nP) (Cohort A, B and C), Gemcitabine (gem) (Cohort A, B and C)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Eileen M O'ReillyMemorial Sloan Kettering Cancer Center, New York, New York, USA rhv@upenn.edu oreillye@mskcc.org.
Christopher R CabanskiParker Institute for Cancer Immunotherapy, San Francisco, California, USA.ORCID http://orcid.org/0009-0007-9938-1331
Jaclyn P LymanParker Institute for Cancer Immunotherapy, San Francisco, California, USA.
Zev A WainbergUniversity of California Los Angeles, Los Angeles, California, USA.
George A FisherDepartment of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Robert A WolffMD Anderson Gastrointestinal Cancer Center, Houston, Texas, USA.
Andrew H KoMedicine (Division of Hematology/Oncology), University of California San Francisco, San Francisco, California, USA.
Mark H O'HaraMedicine, Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID http://orcid.org/0000-0003-2751-6122
Christine N SpencerParker Institute for Cancer Immunotherapy, San Francisco, California, USA.
Jia Xin YuParker Institute for Cancer Immunotherapy, San Francisco, California, USA.
Diane M Da SilvaParker Institute for Cancer Immunotherapy, San Francisco, California, USA.ORCID http://orcid.org/0000-0001-7317-4886
Lacey J PadrónParker Institute for Cancer Immunotherapy, San Francisco, California, USA.
Jamie ArnottParker Institute for Cancer Immunotherapy, San Francisco, California, USA.
Justin FairchildParker Institute for Cancer Immunotherapy, San Francisco, California, USA.
Jonni S MooreAbramson Cancer Center, Philadelphia, Pennsylvania, USA.
Brandon PengUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
William A Hoos1440 Foundation, Scotts Valley, California, USA.
Jill O'Donnell-TormeyCancer Research Institute, New York, New York, USA.
Silvia BoffoBristol Myers Squibb, Princeton, New Jersey, USA.
Ute DuganParker Institute for Cancer Immunotherapy, San Francisco, California, USA.
Alec C KimmelmanNYU Langone Health Perlmutter Cancer Center, New York, New York, USA.
Ravi K AmaravadiUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Robert H VonderheideAbramson Cancer Center, Philadelphia, Pennsylvania, USA rhv@upenn.edu oreillye@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
The RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2006 to 2025
$41.7M
NCI NIH HHS P01 CA117969NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundPatients with metastatic pancreatic ductal adenocarcinoma (mPDAC) often respond to cytotoxic therapy, but early disease progression is typical. Responses to immunotherapy alone are rare. Recent advances in chemoimmunotherapy combinations offer promise. We report results from cohorts A and B of REVOLUTION, an adaptive platform trial designed to evaluate the safety and antitumor activity of chemoimmunotherapy combinations in untreated mPDAC.

methodsREVOLUTION (NCT04787991) is an open-label, exploratory platform trial. Patients were assigned to enrolling cohorts in a non-randomized fashion. All patients received gemcitabine (1,000 mg/m

resultsBoth cohorts enrolled 15 patients. Grade 3-4 treatment-related adverse events occurred in 60% and 53% of patients in cohorts A and B, respectively. One grade 5 event occurred in cohort B, which exhibited more frequent dose modifications and non-compliance. Cohort A demonstrated an ORR of 33% (5/15) and a 12-month OS rate of 65.5% (95% CI 35.7% to 84.0%), with higher baseline levels of programmed cell death protein-1 (PD-1)

conclusionsREVOLUTION cohorts A and B demonstrated encouraging antitumor activity in patients with mPDAC. In cohort B, hydroxychloroquine-related tolerability issues contributed to early discontinuations and reduced drug exposure. These findings highlight the potential and limitations of current chemoimmunotherapy approaches. Although neither cohort will be expanded, the results reinforce the continued promise of chemoimmunotherapy in mPDAC and the importance of refining these strategies.

Indexed as

AdenocarcinomaAlbuminsDeoxycytidineGemcitabineHydroxychloroquineNivolumabPaclitaxelPancreatic NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle Aged130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineGemcitabineHydroxychloroquineNivolumabPaclitaxelBiomarkerChemotherapyCombination therapyImmunotherapySolid tumor

Identifiers

PMID41617393
PMCPMC12863344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.